Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol Myers Squibb EVP, General Counsel Cari Gallman reported that 4,559 restricted stock units vested and converted into 4,559 common shares on October 2, 2026. The units vested in three equal installments beginning October 2, 2024, and each unit converts into one common share upon vesting. Upon vesting, 2,332 common shares were withheld for taxes; the reported price was $61.15 per share.
Bristol Myers Squibb (BMY) director Phyllis R. Yale acquired 560.8970 Deferred Share Units on September 30, 2026. Her reported direct position after the acquisition was 45,980.0770 Deferred Share Units. Each unit converts into a share of common stock upon settlement; the units become settleable when she ceases to be a director or at a future date she previously specified. The units include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb (BMY) director Theodore R. Samuels II acquired 821.3140 Deferred Share Units on September 30, 2026. His resulting direct position was 71,859.0410 Deferred Share Units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Each unit converts into a share of common stock upon settlement; the units become settleable when he ceases to be a director or on a future date he previously specified.
Bristol Myers Squibb director Derica W. Rice acquired 620.994 Deferred Share Units on September 30, 2026. Her reported direct balance after the transaction was 42,084.867 Deferred Share Units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Each unit converts into one common share upon settlement, which becomes available when she ceases to be a director or at a future date she previously specified.
Bristol Myers Squibb director Michael R. McMullen acquired 560.8970 Deferred Share Units on September 30, 2026, bringing his reported balance to 17,050.6010 units. Each unit converts into one share of common stock upon settlement. The units become settleable when he ceases to be a director or at a future date he previously specified.
Bristol Myers Squibb director Peter J. Arduini acquired 560.897 Deferred Share Units on September 30, 2026, bringing his reported direct position to 74,077.176 units. Each unit converts into a share of common stock upon settlement. The reported position includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. No Rule 10b5-1 plan is reported.
BRISTOL MYERS SQUIBB CO (BMY) reported that executive officer Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, sold 6,249 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $64.57 per share. After this transaction, he directly holds 18,748 shares of Bristol Myers Squibb common stock, and no Rule 10b5-1 trading plan is reported.
BRISTOL MYERS SQUIBB CO (BMY) received a Rule 144 notice for a proposed sale of common stock by Cristian Massacesi. The filing covers 6,249 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $403,497.93 and a proposed sale date of September 9, 2026 on the NYSE.
The shares to be sold arise from restricted stock vesting on August 1, 2026 as compensation from the issuer. The notice is signed by Jessica Spraker as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Cristian Massacesi.
Bristol Myers Squibb Co (BMY) reported that executive vice president of Corporate Affairs Wendy Bartie Short had 1,236 Restricted Stock Units vest and convert into an equal number of shares of common stock on September 1, 2026. The related RSU award was granted to vest in four equal installments beginning September 1, 2023.
Of the vested shares, 633 shares of common stock were withheld to pay tax liabilities at a reported value of $66.92 per share, leaving the remainder effectively delivered to her as directly owned common stock. Following the vesting, the underlying RSU derivative position reported on this form was reduced to zero.
BRISTOL MYERS SQUIBB CO (BMY) reported that Phil M. Holzer, its SVP and Controller, sold 500 shares of common stock on 2026-08-25 in a sale in open market or private transaction at a price of $67.50 per share. Following this transaction, Holzer directly holds 16,862 shares of BMY common stock. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.